Botryoid Embryonal Rhabdomyosarcoma of the Uterine Cervix in Nulliparous Woman: Fertility-Conscious Multimodal Management of IRSG Group III Disease
International Journal of Drug Delivery Technology · 29.05.2026 · 16 (40s)
DOI: 10.25258/ijddt.16.40s.39 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 29.05.2026. Verfasst von Gandhi Singgih Nugroho und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Botryoid embryonal rhabdomyosarcoma (ERMS) of the uterine cervix is an uncommon mesenchymal malignancy in reproductive-aged women. The botryoid variant typically demonstrates polypoid morphology and favorable chemosensitivity, yet prognosis depends critically on tumor burden and completeness of local control. Adult cervical ERMS is rare and underrepresented in prospective trials, posing unique diagnostic and therapeutic dilemmas—especially when fertility preservation is desired. Case presentation: A 28-year-old nulliparous woman (P0000) presented with intermittent postcoital bleeding for ~12 months. Speculum examination revealed a friable, hump-shaped polypoid cervical mass that bled on contact. Pelvic MRI showed a large cervical tumor measuring 11.3 × 9.1 × 12.9 cm confined to the cervix without radiologic distant metastasis. Incisional biopsy demonstrated small round to spindle tumor cells with a subepithelial cambium layer; immunohistochemistry was positive for desmin, myogenin, and MyoD1—confirming botryoid ERMS. Because no complete surgical resection was performed and gross tumor remained, the case was classed as IRSG Group III. Given the large tumor burden and the patient’s strong fertility desire, a fertility-conscious strategy was adopted: neoadjuvant systemic chemotherapy with six cycles of vincristine, actinomycin-D, and cyclophosphamide (VAC), with monthly clinical follow-up and interval MRI for response assessment.
Conclusion
This case underscores (1) the need for high clinical suspicion and prompt tissue diagnosis for persistent abnormal bleeding, (2) the prognostic importance of tumor size and IRSG grouping in adult cervical ERMS, and (3) the pragmatic role of neoadjuvant VAC to downstage bulky Group III disease in patients seeking fertility preservation.
Zitieren
APA
Nugroho, G. S., & Tjokroprawiro, B. A. (2026). Botryoid Embryonal Rhabdomyosarcoma of the Uterine Cervix in Nulliparous Woman: Fertility-Conscious Multimodal Management of IRSG Group III Disease. International Journal of Drug Delivery Technology, 16(40s). https://doi.org/10.25258/ijddt.16.40s.39
Vancouver
Nugroho GS, Tjokroprawiro BA. Botryoid Embryonal Rhabdomyosarcoma of the Uterine Cervix in Nulliparous Woman: Fertility-Conscious Multimodal Management of IRSG Group III Disease. International Journal of Drug Delivery Technology. 2026;16(40s). doi:10.25258/ijddt.16.40s.39
BibTeX
@article{Nugroho2026,
author = {Nugroho, Gandhi Singgih and Tjokroprawiro, Brahmana Askandar},
title = {Botryoid Embryonal Rhabdomyosarcoma of the Uterine Cervix in Nulliparous Woman: Fertility-Conscious Multimodal Management of IRSG Group III Disease},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {40s},
doi = {10.25258/ijddt.16.40s.39}
}
EUVIMED